Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205217 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL4034005 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL18047420 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL4756904 | 0.84 | RAB9A (0.60) | SMN1; SMN2CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL17307104 | 0.83 | NPC1 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL10917021 | 0.83 | FABP7 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL6666657 | 0.83 | FABP7 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL280126 | 0.83 | FABP7 (0.58) | SMN1; SMN2CYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL6642777 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AMAPT | |
| SCHEMBL8173819 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19NPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102712626-B | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2014-09-17 | — | — | CN | disclosed |
| CN-102712626-A | Piperazine compounds having PGDS inhibitory effect | TAIHO PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | SMN1; SMN2 3430/4885CYP2C19 595/4885NPC1 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.